Discover Fabrazyme® (agalsidase beta), the only ERT (enzyme replacement therapy) indicated for patients 2 years and older with Fabry disease. See website for Important Safety Information & Full Prescribing Information including Boxed WARNING.

What is Fabrazyme® (agalsidase beta)? See how Fabrazyme® helps to clear GL-3 accumulation in the body, clinical trial results, and side effects. See website for Important Safety Information & Full Prescribing Information including Boxed WARNING.

Fabrazyme can cause serious side effects, including: Severe Allergic Reactions Including Anaphylaxis. Approximately 1% of patients who received Fabrazyme experienced a severe allergic or anaphylactic reaction during their infusion. Some of these reactions were life-threatening, and included:

Fabrazyme® (agalsidase beta) is the first and only enzyme replacement therapy (ERT) approved for the treatment of patients 2 years of age and older with confirmed Fabry disease. See website for Important Safety Information & Full Prescribing Information including Boxed WARNING.

Fabrazyme is a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease. (1)

See the Fabrazyme® (agalsidase beta) mechanism of action and how Fabrazyme® works to clear accumulated GL-3 in major organs. See website for Important Safety Information & Full Prescribing Information including Boxed WARNING.

For step-by-step instructions on how to calculate dose, preparation for use, storage and handling, and administering Fabrazyme, download the Fabrazyme Preparation & Administration Info Sheet. Watch this tutorial video to lean more about administering Fabrazyme.

Fabrazyme helps patients with Fabry disease by replacing a missing or deficient enzyme. It has been used to treat people with Fabry disease for 20+ years and is backed by the safety and effectiveness shown in clinical studies.

Initiate FABRAZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g. anaphylaxis) occurs, discontinue FABRAZYME and immediately initiate appropriate medical treatment, including use of epinephrine.

Initiate FABRAZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g. anaphylaxis) occurs, discontinue FABRAZYME and immediately initiate appropriate medical treatment, including use of epinephrine.